Osteocis (Sodium Oxidronate)

Sodium Oxidronate, the active ingredient in Osteocis, is a bisphosphonate presented as a oral tablet for systemic use. It treats osteoporosis and related bone density disorders in post‑menopausal women and men at risk of fracture. GNH USA supplies Osteocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Osteocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osteocis is a bisphosphonate that acts on bone metabolism to reduce fracture risk.

- Osteoporosis: Improves bone mineral density and lowers the incidence of vertebral and hip fractures. - Paget's disease of bone: Helps normalize bone remodeling and reduces bone pain. - Osteogenesis imperfecta: Supports increased bone strength and reduces fracture frequency.

Adverse reactions to Sodium Oxid‑​ ​  ​  ​  ​  ​  ​  ​  …  … …  … …  …  …

Common Side Effects: - Nausea  -  C        …  ...  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  -  …  ...  ...  ...  ...  - … ...  ...  ...  ...  ...  - … … …  ...  ...  ...  ...  - … … …  …  …  …  …  …  …  -  …  …  …  ... …  … 

Serious or Rare ...  ....  ....  …  …